Compare Bumble Inc (BMBL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumble Inc vs Sanofi SA — how do they compare? Bumble Inc trades at $3.11 (market cap $382.16M), while Sanofi SA trades at $43.67 (market cap $102.91B). The key difference: Sanofi SA is far larger — about 269.3× Bumble Inc's market cap, and Sanofi SA pays a 5.6% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| BMBL | SNY | |
|---|---|---|
Market Cap | $382.16M | $102.91B |
Sector | Technology | Health |
52-Week High | $8.57 | $52.34 |
52-Week Low | $2.70 | $41.33 |
Enterprise Value | $733.84M | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMBL trades at $3.11, up 2.64% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported a Q1 2026 EPS beat but faces declining revenue and a net loss of -$693.14M for 2025. Recent news highlights a potential sale exploration and an AI-driven product overhaul to counter slowing growth and payer declines.
Outlook remains speculative with a consensus price target of $4.37, offering 40% upside, but risks include persistent losses, high debt, and intense competition. Execution of the strategic reset is critical for a turnaround, with cash flow improvements providing a slight cushion amid operational challenges.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
